Sopharma Trading AD (XBUL:SFT) Debt-to-EBITDA : (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XBUL:SFT Sopharma Trading AD XBUL:SFT
84 GF Score
Price €3.02
GF Value €7.30
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Sopharma Trading AD Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Sopharma Trading AD's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was €123 Mil. Sopharma Trading AD's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was €59 Mil. Sopharma Trading AD's annualized EBITDA for the quarter that ended in Jun. 2026 was €63 Mil. Sopharma Trading AD's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 was 2.91.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Sopharma Trading AD's Debt-to-EBITDA or its related term are showing as below:

XBUL:SFT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.75   Med: 6.08   Max: 8.84
Current: 2.89

During the past 13 years, the highest Debt-to-EBITDA Ratio of Sopharma Trading AD was 8.84. The lowest was 2.75. And the median was 6.08.

XBUL:SFT's Debt-to-EBITDA is ranked worse than
59.14% of 93 companies
in the Medical Distribution industry
Industry Median: 2.29 vs XBUL:SFT: 2.89

Sopharma Trading AD  (XBUL:SFT) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Sopharma Trading AD Debt-to-EBITDA Related Terms

Sopharma Trading AD Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Sopharma Trading AD's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sopharma Trading AD Debt-to-EBITDA Chart

Sopharma Trading AD Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sopharma Trading AD Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

XBUL:SFT vs MCK, COR, CAH: Debt-to-EBITDA Comparison

For the Medical Distribution subindustry, Sopharma Trading AD's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sopharma Trading AD Debt-to-EBITDA vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sopharma Trading AD's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Sopharma Trading AD's Debt-to-EBITDA falls into.


XBUL:SFT
84GF Score
Sopharma Trading AD XBUL:SFT
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sopharma Trading AD Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Sopharma Trading AD's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(124.83922371519 + 53.427436877544) / 67.300335905006
=2.65

Sopharma Trading AD's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(123.287 + 58.908) / 62.608
=2.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Is Sopharma Trading AD (XBUL:SFT) Overvalued in 2026?

Based on GuruFocus' analysis, Sopharma Trading AD stock appears to be undervalued. The current stock price of €3.02 is trading 58.6% below its estimated GF Value™ of €7.30. GuruFocus considers Sopharma Trading AD to be Significantly Undervalued.

Key valuation signals for XBUL:SFT:

  • Debt-to-EBITDA:
  • GF Value™: €7.30 vs. price of €3.02 (58.6% below fair value)
  • GF Score™: 84/100 with 2 warning signs

No single metric tells the full story. See the XBUL:SFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sopharma Trading AD Business Description

Address Sunrise Street, Lachezar Stanchev, 5 Sopharma, Business Towers, Building A Floor 12, Sofia, BGR, 1756
Sopharma Trading AD is a Bulgaria based company operating in the pharmaceutical sector. The company is engaged in the distribution of pharmaceutical items, including a portfolio of international brands, medicinal products, medical supplies, sanitary and hygienic materials, vitamins, nutritional supplements, cosmetics, medical equipment, and equipment. It also provides turnkey solutions for the construction of medical and hospital establishments. In addition, the group also caters logistics solutions for import, storage, and distribution of goods to end customers.
84GF Score

Get the complete analysis for XBUL:SFT

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.02
Price
€7.30
GF Value